Clinical Trial Reveals HTERT Vaccination Induces Immune Response In Resistant Cancers

In a notable advancement in the realm of cancer immunotherapy, a Phase 1 clinical trial has been detailed in the latest issue of Experimental Biology and Medicine, showcasing a new approach towards the active immune therapy of cancer. The study, led by James Spicer and his team at King’s College London, focuses on a vaccination strategy targeting human telomerase reverse transcriptase (hTERT), a component overexpressed in the majority of malignancies. This innovative trial, titled "A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms", marks a significant step forward in combating solid tumours.

The primary aim of this pioneering research was to evaluate the safety and tolerability of the hTERT vaccine alongside adjuvants. Additionally, the study sought to explore immune response outcomes and the presence of antigen-specific T cells, with Shahram Kordasti’s immunopathology team playing a crucial role in these analyses. The findings from this trial are promising, demonstrating not only the safety and feasibility of this vaccination-mediated approach for solid tumours but also significant immunological responses, including the clonal expansion of hTERT reactive T cells. Furthermore, a noteworthy outcome was the stabilization of disease for at least six months in a quarter of patients who had previously shown resistance to therapy.

Professor Spicer's leadership in this trial was driven by the urgent need to overcome major hurdles in cancer treatment, such as the activation of effector T cells and overcoming immune cell suppression. The study included patients with various types of multiply pre-treated solid tumours, employing an hTERT-derived 7-peptide library created by Farzin Farzaneh’s group at King’s. This library ensures antigen presentation compatibility with both HLA class-I and class-II across 90% of a European population. The use of Montanide adjuvant and a topical TLR-7 agonist aimed to enhance antigen presentation, while the addition of oral low-dose cyclophosphamide and celecoxib targeted regulatory T cell modulation and cyclooxygenase-2-mediated immunosuppression respectively.

Expressing his views on the trial's outcomes, Professor Spicer stated, "Our findings represent a significant advance in cancer immunotherapy. The safety and efficacy demonstrated in this Phase 1 trial underscore the potential of hTERT vaccination and immune-suppressor control strategies in reshaping cancer treatment." Echoing this sentiment, Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, highlighted the trial as unveiling a promising new frontier in cancer treatment that could lead to improved therapeutic strategies for patients.

This groundbreaking study received funding from Candles Charity, reflecting the potential impact and importance of such research in advancing cancer treatment options. Experimental Biology and Medicine continues to be at the forefront of publishing multidisciplinary and interdisciplinary research in biomedical sciences since its establishment in 1903. As the journal of the Society of Experimental Biology and Medicine, it serves as a platform for scientists to share significant developments in medical research.

For those interested in further details about society membership or publishing opportunities within Experimental Biology and Medicine, more information can be found on their official website.